Time：2025-11-11
Medtide Inc. ("the Company"; Stock Code: 3880) has been officially named a 2025 "Hangzhou Headquarters Enterprise", in recognition of its leading comprehensive strength in peptides and oligonucleotides. The honor underscores the company’s pivotal role in headquarters economy and its benchmark status in the global peptide and oligonucleotide drug R&D, production and service sector.
About Medtide Inc.
Medtide Inc. is a peptide-focused contract research, development, and manufacturing organization (CRDMO), offering full-cycle services ranging from early-stage discovery, pre-clinical research and clinical development to commercial-stage production. The company is headquartered in Hangzhou, China, and has commercial production bases and offices in both China and the United States. We have been deeply involved in the peptide field for over 20 years. Today, we have become a CRDMO with global operations and comprehensive service capabilities.
Medtide Inc. provides (i) contract research organization (CRO) services, namely peptide new chemical entity (NCE) discovery synthesis; and (ii) contract development and manufacturing organization (CDMO) services, namely peptide chemistry, manufacturing and controls (CMC) development and commercial manufacturing. We have established global operations, with projects covering over 50 countries, including major markets such as China, the United States, Japan, Europe, South Korea, and Australia. We provide our 1000+ customers with peptide drug development, production, and CMC documentation and filing support services that meet regulatory requirements in major markets worldwide.
As a trusted and sustainable enterprise, Medtide Inc. has established long-term partnerships with many customers. Through close collaboration, we assist customers in bringing drugs that profoundly impact human health to the market, focusing on patients and committed to improving their lives, thus promoting the development of the human health industry.
